Canada’s Drug Agency | Drugs, Health Technologies and Systems.

blinatumomab

Details

Files
Generic Name:
blinatumomab
Project Status:
Active
Therapeutic Area:
B-cell precursor acute lymphoblastic leukemia
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Blincyto
Project Line:
Reimbursement Review
Project Number:
PC0365-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult and pediatric patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy in the frontline setting.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult and pediatric patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy in the frontline setting.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open06-Sep-24
Call for patient/clinician input closed25-Nov-24
Submission received18-Oct-24
Submission accepted01-Nov-24
Review initiated04-Nov-24
Draft CADTH review report(s) provided to sponsor for comment31-Jan-25
Deadline for sponsors comments07-Feb-25
CDA-AMC review report(s) and responses to comments provided to sponsor28-Feb-25
Expert committee meeting (initial)12-Mar-25
Draft recommendation issued to sponsor25-Mar-25
Draft recommendation posted for stakeholder feedback03-Apr-25
End of feedback period17-Apr-25
Final recommendation issued to sponsor and drug plans01-May-25
Final recommendation posted-
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)15-May-25
CDA-AMC review report(s) posted-

Files

Draft Recommendations & Reasons View PDF
Patient and Clinician Group input View PDF
Last Updated : April 23, 2025